Abstract:BACKGROUND: Cardiac channelopathies, caused by mutations in ion-channel genes, can lead to sudden cardiac death (SCD) via ventricular arrhythmias. Brugada syndrome (BrS) is a rare inherited channelopathy characterized by a unique ECG pattern and a high incidence of ventricular fibrillation leading to SCD in the absence of structural heart defects. The main gene responsible for 20-25% of BrS cases is SCN5A, encoding the cardiac sodium channel alpha-subunit Nav1.5, which carries the sodium current (INa) responsible for the rapid depolarization phase of the action potential (AP). While current treatments do not target the genetic cause of channelopathies, this study explores the therapeutic potential of overexpressing the N-terminal region of Nav1.5 (Nter) to restore electrical activity by rescuing INa, in the context of SCN5A deficiency. METHODS: We overexpressed the Nter peptide using viral vectors in Scn5a+/- mice, in CRISPR/Cas9 edited-SCN5A+/- cardiomyocytes derived from induced-pluripotent stem cells (iPSC-CMs) and in BrS patient iPSC-CMs. We assessed molecular and functional effects of Nter overexpression in vitro and in vivo by measuring Nav1.5 subcellular expression and electrophysiological activity and by recording ECGs and arrhythmias. RESULTS: Whereas Scn5a+/- mice showed an impaired INa associated with a slowed-cardiac conduction characteristic of the BrS phenotype, cardiac-specific overexpression of Nter corrected AP parameters by restoring INa density in Scn5a+/- mouse cardiomyocytes. This increase in INa density was caused by a translocation of Nav1.5 to the cell membrane in Nter-overexpressing mice. Most importantly, Nter overexpression normalized atrioventricular and ventricular conduction and protected Scn5a+/- mice from arrhythmias triggered by programmed electrical stimulation. Similarly, Nter overexpression in SCN5A+/- human iPSC-CMs led to a 2-fold increase in Nav1.5 cell-surface expression, resulting in normalization of INa and AP parameters and abolition of early after depolarizations observed during spontaneous AP recordings. Similar results were obtained in iPSC-CMs derived from a BrS patient, confirming the potential of this therapy in human models. CONCLUSIONS: This study identified a novel therapeutic peptide effective in restoring cardiac excitability in animal and cellular models of BrS, paving the way for future development of therapies for life-threatening arrhythmias in patients with SCN5A deficiency.

MOG1 rescues defective trafficking of nav1.5 mutations in brugada syndrome and sick sinus syndrome

MOG1 Restores the Expression and Function of SCN5A-p.R104W Through Sec23a-Mediated Forward Trafficking

Gene therapy targeting protein trafficking regulator MOG1 in mouse models of Brugada syndrome, arrhythmias, and mild cardiomyopathy

Mechanistic insights into the interaction of the MOG1 protein with the cardiac sodium channel Nav1.5 clarify the molecular basis of Brugada syndrome.

Abstract 1503: Knockdown of Mog1 Expression Reduces Sodium Currents by Reducing the Trafficking of Cardiac Sodium Channel Na V 1.5 to the Cell Membrane

Mechanistic insights into the interaction of cardiac sodium channel Nav1.5 with MOG1 and a new molecular mechanism for Brugada syndrome

Patient-specific Ipsc-Derived Cardiomyocytes Reveal Aberrant Activation of Wnt/β-catenin Signaling in SCN5A-related Brugada Syndrome

Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome

Identification Of A New Co-Factor, Mog1, Required For The Full Function Of Cardiac Sodium Channel Na(V)1.5

Cardiac Sodium Channel Regulator Mog1 Regulates Cardiac Morphogenesis And Rhythm

Mog1 Deficiency Promotes Cardiac Contractile Dysfunction and Isoproterenol-Induced Arrhythmias Associated with Cardiac Fibrosis and Cx43 Remodeling

Small GTPases SAR1A and SAR1B Regulate the Trafficking of the Cardiac Sodium Channel Na(v)1.5

Abstract 111: Wnt Signaling Inhibition Rescues Voltage-Gated Na + Current in Brugada Syndrome Patient Cardiomyocytes

Gene Therapy with the N-terminal Fragment of Nav1.5 for Cardiac Channelopathies: A Novel Transcomplementation Mechanism Potentiating the Cardiac Sodium Current

1-Deoxynojirimycin Promotes Cardiac Function and Rescues Mitochondrial Cristae in Mitochondrial Hypertrophic Cardiomyopathy.

Functional Analysis of a Novel SCN5A Mutation G1712C Identified in Brugada Syndrome

In vivo Dominant-Negative Effect of an SCN5A Brugada Syndrome Variant

Compound Heterozygous Mutations P336L and I1660V in the Human Cardiac Sodium Channel Associated with the Brugada Syndrome.

Small GTPases SAR1A and SAR1B Regulate the Trafficking of the Cardiac Sodium Channel Nav1.5.

De Novo Mutation in the SCN5A Gene Associated with Brugada Syndrome.

A Novel Cardiac Nav1.5 Channel Mutation, L812Q, Leads to Brugada Syndrome